Persbericht

12/12/2019 European Commission Approves EVENITY® (Romosozumab) for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture (12.12.2019)
11/12/2019 Total Libya - Agreement Between NOC and Total Endorsing the Groups Entry into the Waha Concessions (11.12.2019)d
11/12/2019 ENGIE and Meridiam awarded 50-year Utility Management Concession Univ Iowa toward zero-carbon transition (11.12.2019)
11/12/2019 Ahold Delhaize to invest $480 million in U.S. supply chain to create a fully integrated, self-distribution model (11.12.2019
11/12/2019 Nyrstar- Results of the extraordinary general shareholders' meeting held on 9 December 2019 (11.12.2019)
10/12/2019 Ackermans Van Haaren - DEME Verkoop van 100% van participatie in offshore windmolenpark Merkur (10.12.2019)
10/12/2019 Total - Citeo, Total, Recycling Technologies, Mars and Nestlé Join Forces to Develop Chemical Recycling of Plastics in France (10.12.2019)
10/12/2019 EURONEXT - ANNOUNCES BINDING AGREEMENT TO SELL ITS 20% MINORITY STAKE IN EUROCCP (10.12.2019)
10/12/2019 UCB - Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting (10.12.2019)
10/12/2019 Nyrstar - Results of the extraordinary general shareholders meeting held on 10 december (10.12.2019)
09/12/2019 bpost - & BD myShopi sluiten overeenkomst voor overname van CityDepot activiteiten (9.12.2019)
06/12/2019 Celyad Receives Additional €2.5 Million in Non-Dilutive Funding (6.10.2019)
06/12/2019 TINC - Openbaarmaking conform de transparantiewet (6.12.2019)
06/12/2019 EURONEXT - ANNOUNCES VOLUMES FOR NOVEMBER 2019 (6.12.2019)
06/12/2019 Fagron - Disclosure of received notifications (6.12.2019)
06/12/2019 UCB - Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira® (6.12.2019)
06/12/2019 Nyrstar - Publication of First Half 2019 Consolidated Accounts (6.12.2019)
06/12/2019 Galapagos - voltooit de rekrutering van de NOVESA studie in patiënten met systemische sclerose (6.12.2019)
06/12/2019 Brederode - TUSSENTIJDSE INFORMATIE (6.12.2019)
06/12/2019 Quest for growth - NAV per aandeel op 30112019 7,90 € (6.12.2019)